In the absence of a submission from the holder of the marketing authorisation, human normal immunoglobulin (Aragam®) cannot be endorsed for use within NHS Wales for replacement therapy in primary immunodeficiency syndromes such as: congenital agammaglobulinemia and hypogammaglobulinemia; common variable immunodeficiency; severe combined immunodeficiency and Wiskott Aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinemia and recurrent infections; children with congenital AIDS and recurrent infections; immunomodulation; idiopathic thrombocytopenic purpura; children or adults at high risk of bleeding or prior to surgery to correct the platelet count; Guillain Barré syndrome; Kawasaki disease; allogeneic bone marrow transplantation.